Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial - PubMed
3 hours ago
- #Multiple Myeloma
- #Mass Spectrometry
- #Minimal Residual Disease
- Mass spectrometry (MS) reliably detects monoclonal proteins in multiple myeloma patients, offering a minimally invasive approach.
- MS negativity at later time points, particularly 12 months of maintenance, is strongly associated with superior progression-free survival (hazard ratio 0.25).
- Combined assessment of MS with bone-marrow measurable residual disease (MRD) improves risk stratification, with double-positive patients having the worst outcomes.
- MS demonstrates higher sensitivity than serum protein electrophoresis at low concentrations for accurate M-protein detection.
- The findings support serum MS as a practical biomarker for monitoring disease, complementing MRD in response assessment and treatment strategies.